Recombinant Human E3 ubiquitin-protein ligase synoviolin (SYVN1)

What is the molecular structure of SYVN1 and how does it contribute to its function?

SYVN1, also known as Hrd1 or Der3, is an ER-resident E3 ubiquitin ligase characterized by its RING domain, which is essential for its ubiquitin ligase activity. The protein contains a SyU domain with evolutionarily conserved arginine residues (R266/R267) that are crucial for substrate binding . The RING domain contains cysteine residues that are vital for its catalytic function, as demonstrated by the C329S mutation which diminishes its E3 ligase activity .

The functional domains of SYVN1 work cooperatively to recognize, bind, and ubiquitinate target proteins. This structure allows SYVN1 to participate in the ERAD pathway, where it tags misfolded or unneeded proteins for proteasomal degradation. Experimental approaches to study these structural elements typically involve site-directed mutagenesis, such as the RING domain mutant (SYVN1 C329S) which has significantly reduced ubiquitination activity compared to wild-type SYVN1 .

How do researchers produce and validate recombinant SYVN1 for experimental use?

For recombinant SYVN1 production, researchers typically use mammalian expression systems (HEK 293T cells) rather than bacterial systems due to the need for proper protein folding and post-translational modifications. The methodological approach involves:

• Cloning the full-length human SYVN1 cDNA into expression vectors with tags (FLAG, HA) for detection and purification

• Transfecting expression vectors into mammalian cells using Lipofectamine 2000 or similar reagents

• Harvesting cells after 24-48 hours and lysing in appropriate buffers (typically containing 20 mM Tris-HCl, pH 8.0; 100 mM NaCl; 1 mM EDTA; 1% NP-40; and protease inhibitors)

• Purifying recombinant protein using affinity chromatography based on the attached tags

Validation of recombinant SYVN1 functionality should include in vitro ubiquitination assays containing ATP, ubiquitin, E1, E2, and the substrate protein to confirm E3 ligase activity . Western blotting is then used to detect polyubiquitinated products.

How does SYVN1 regulate ER morphology and what are the implications for cellular function?

SYVN1 regulates ER morphology primarily through its interaction with and ubiquitination of Atlastins (ATLs), particularly ATL1. Research has demonstrated that overexpression of SYVN1 disrupts the normal ER network structure, leading to abnormal ER morphology . This disruption appears to be dependent on SYVN1's E3 ubiquitin ligase activity, as the RING domain mutant SYVN1 C329S shows significantly reduced capacity to alter ER structure .

The mechanism involves SYVN1-mediated ubiquitination of ATL1, which inhibits ATL1's GTPase activity without causing protein degradation . Since ATL1 is critical for mediating homotypic membrane fusion in the ER, this inhibition directly affects ER tubule formation and network maintenance. Interestingly, co-expression of ATL1 with SYVN1 partially recovers normal ER structure, suggesting a balanced regulatory relationship .

Functionally, this regulation impacts ER-dependent cellular processes, particularly COPII vesicle export. Studies measuring SEC31A puncta (a marker for COPII vesicles) show that SYVN1 overexpression decreases COPII vesicle formation by approximately 30%, while co-expression with ATL1 restores vesicle numbers to normal levels . This indicates SYVN1's crucial role in membrane trafficking and protein transport from the ER to the Golgi apparatus.

What role does SYVN1 play in ER stress and the unfolded protein response?

SYVN1, as a key ERAD E3 ubiquitin ligase, functions as a critical regulator during ER stress and the unfolded protein response (UPR). When the ER experiences stress due to accumulation of misfolded proteins, SYVN1 mediates the ubiquitination of these proteins, targeting them for proteasomal degradation to maintain ER homeostasis.

Research has shown that SYVN1 knockdown results in increased levels of ER stress markers such as GRP78 (Glucose-regulated protein 78) and CHOP (C/EBP homologous protein) . In a study using AAV-mediated SYVN1 knockdown in rat striatum neurons, researchers observed significantly elevated levels of both GRP78 and CHOP compared to control groups . This demonstrates that reduced SYVN1 activity impairs the cell's ability to resolve ER stress, potentially leading to prolonged UPR activation.

The methodological approach to study this connection includes:

• Knockdown of SYVN1 using shRNA delivered via lentiviral or AAV vectors

• Measurement of ER stress markers by Western blotting

• Subcellular fractionation to isolate ER compartments and analyze protein accumulation in different cellular locations

This research highlights SYVN1's importance in preventing chronic ER stress, which can lead to cellular dysfunction and contribute to various pathological conditions.

How does SYVN1 interact with Atlastins to regulate ER morphology?

SYVN1 directly interacts with Atlastins (ATLs), particularly ATL1, to control ER shape through a ubiquitination mechanism that surprisingly does not lead to protein degradation. In experimental studies, SYVN1 has been shown to ubiquitinate ATL1 predominantly at the K285 residue and to a lesser extent at K287 . This ubiquitination event functionally inhibits ATL1's GTPase activity rather than targeting it for degradation.

The interaction mechanism has been characterized through immunoprecipitation assays that demonstrate the physical binding between SYVN1 and ATL1 in both overexpression systems and under endogenous conditions . The functional relationship between these proteins is evidenced by ER morphology rescue experiments, where abnormal ER structure caused by SYVN1 overexpression can be partially normalized by co-expressing ATL1 .

This SYVN1-ATL1 regulatory axis directly impacts ER-Golgi trafficking, as measured by the formation of COPII vesicles marked by SEC31A. Quantitative analysis shows that SYVN1 overexpression reduces SEC31A-positive vesicles by approximately 30%, while co-expression with ATL1 restores vesicle counts to control levels . This suggests a balance between these proteins is essential for normal ER function and morphology.

What is the molecular mechanism of PGC-1β regulation by SYVN1 and how does it impact energy metabolism?

SYVN1 regulates peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC-1β) through direct ubiquitination, establishing a critical link between ERAD and energy metabolism. Research has identified the precise molecular interaction: SYVN1 contains a SyU domain with conserved arginine residues (R266/R267) that are crucial for binding to PGC-1β, while PGC-1β's binding domain maps to amino acids 195-367, containing an LXXLL motif .

This interaction has been validated through multiple experimental approaches:

• GST pull-down assays to map the binding domains

• Co-immunoprecipitation studies in HEK 293T cells with overexpressed proteins

• Endogenous immunoprecipitation demonstrating physiologically relevant interaction

Functionally, SYVN1 ubiquitinates PGC-1β and targets it for proteasomal degradation, as demonstrated through in vitro ubiquitination assays with ATP, HA-Ub, E1, E2, and SYVN1 . The significance of this regulation is evident in SYVN1-deficient mice, which show upregulation of PGC-1β target genes, increased mitochondrial number and respiration, and elevated basal energy expenditure in adipose tissue .

The metabolic consequences of this regulatory mechanism are substantial: SYVN1 knockout mice exhibit resistance to weight gain and reduced white adipose tissue accumulation, even in genetically obese (ob/ob and db/db) backgrounds . This positions SYVN1 as a potential therapeutic target for obesity treatment.

How does SYVN1 deficiency affect body weight and adipose tissue development?

SYVN1 deficiency leads to significant changes in body weight regulation and adipose tissue development through multiple mechanisms. Studies using conditional SYVN1 knockout mice demonstrated weight loss and reduced white adipose tissue accumulation compared to control animals . This phenotype was observed not only in otherwise wild-type animals but also in genetically obese (ob/ob and db/db) mouse models .

The underlying mechanism involves SYVN1's regulation of PGC-1β, a key thermogenic coactivator. When SYVN1 is absent, PGC-1β protein levels increase due to reduced ubiquitination and subsequent degradation . This leads to upregulation of PGC-1β target genes involved in mitochondrial biogenesis and energy expenditure.

Quantitative analysis of adipose tissue from SYVN1-deficient mice revealed:

• Increased mitochondrion number

• Enhanced respiratory capacity

• Elevated basal energy expenditure

These metabolic changes collectively contribute to reduced adiposity and resistance to obesity. Importantly, the selective SYVN1 inhibitor LS-102 was shown to prevent weight gain in mice, highlighting the potential therapeutic application of targeting this pathway for obesity treatment .

What is the relationship between SYVN1, inflammation, and metabolic regulation?

SYVN1 represents an important molecular link between inflammatory signaling and metabolic regulation. Research has established that SYVN1 is a key target for inflammatory cytokines including tumor necrosis factor α (TNFα), interleukin-1 (IL-1), and interleukin-17 (IL-17) . This connection is particularly significant given the well-established role of chronic inflammation in metabolic disorders.

The relationship between SYVN1 and inflammation extends to its roles in rheumatoid arthritis and fibrosis, conditions with strong inflammatory components . The molecular mechanisms involve cytokine-mediated regulation of SYVN1 expression, which in turn affects metabolic parameters through multiple pathways, including PGC-1β regulation.

To study this relationship experimentally, researchers have employed several approaches:

• Analysis of SYVN1 expression levels in response to inflammatory cytokine treatment

• Examination of metabolic parameters in conditions of both inflammation and SYVN1 modulation

• Luciferase reporter assays to measure the impact of SYVN1 on transcriptional activity of metabolic regulators like PPARα

The experimental evidence suggests a model where inflammatory signals upregulate SYVN1, which then suppresses PGC-1β activity, potentially contributing to the metabolic dysfunction observed in inflammatory conditions. This positions SYVN1 as a potential therapeutic target at the intersection of inflammation and metabolism.

How is SYVN1 involved in neurological functions and pathologies?

SYVN1 has emerging roles in neurological function through its regulation of key neuronal proteins. Research has revealed that SYVN1 mediates the ubiquitination and degradation of GABA A receptor α1 subunit (GABA Aα1) in the dorsal striatum (Dstr), particularly in the context of methamphetamine (METH) conditioned place preference (CPP) . This finding connects SYVN1 to neurotransmitter receptor homeostasis and potentially to addiction-related neuroadaptations.

Experimental evidence supporting this neurological role comes from both in vitro and in vivo studies:

• In primary Dstr neurons, SYVN1 knockdown via lentiviral shRNA significantly increased GABA Aα1 expression by approximately 80% compared to controls

• In vivo AAV-mediated SYVN1 knockdown in rat striatum similarly increased GABA Aα1 protein levels by approximately 52%

• Subcellular fractionation studies demonstrated that this increased GABA Aα1 accumulates specifically in the intra-ER fraction rather than the extra-ER compartment

These findings suggest that SYVN1 functions in quality control of GABA Aα1 receptors during their biosynthesis and processing in the ER. Dysfunction in this pathway could potentially contribute to altered inhibitory neurotransmission and neurological disorders associated with GABAergic signaling imbalance.

What are the implications of SYVN1's regulation of Atlastins for neurodegenerative diseases?

SYVN1's regulation of Atlastins, particularly ATL1, has significant implications for neurodegenerative diseases, especially hereditary spastic paraplegia (HSP). ATL1 is a dynamin-like GTPase critical for ER membrane fusion, and defects in ATL1 function are directly linked to HSP, a neurodegenerative condition characterized by progressive spasticity .

Research has established that SYVN1 ubiquitinates ATL1 primarily at residue K285, with secondary ubiquitination at K287 . This modification inhibits ATL1's GTPase activity without triggering protein degradation, thereby modulating ER morphology and function. The abnormal ER structure resulting from dysregulated SYVN1-ATL1 interaction may contribute to neuronal dysfunction observed in HSP.

The functional consequence of this regulation extends to COPII vesicle formation and trafficking, which is essential for neuronal protein delivery and axonal maintenance. Quantitative analysis shows that SYVN1 overexpression reduces COPII vesicle formation by approximately 30%, an effect that can be counteracted by ATL1 co-expression .

These findings suggest potential therapeutic approaches targeting the SYVN1-ATL1 axis for HSP and possibly other neurodegenerative conditions involving ER dysfunction. Modulating SYVN1 activity could potentially normalize ATL1 function and restore proper ER morphology and trafficking in affected neurons.

What are the optimal techniques for detecting SYVN1-substrate interactions?

Detecting SYVN1-substrate interactions requires a combination of complementary techniques to establish both physical binding and functional ubiquitination. Based on published research methodologies, the following approach is recommended:

For physical interaction detection:

• Co-immunoprecipitation (Co-IP): The gold standard for detecting protein-protein interactions in cells. For SYVN1 studies, cell lysates should be prepared in a buffer containing 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, 1% NP-40, and protease inhibitors . When studying endogenous interactions, a more specialized buffer composition is recommended: 100 mM Tris-HCl, 80 mM NaCl, 1 mM EDTA, 5 mM EGTA, 5% glycerol, 2% digitonin, 0.1% Brij 35, protease inhibitor cocktail, and 20 mM MG132 .

• GST pull-down assays: For mapping specific binding domains. This approach successfully identified that SYVN1 binds to PGC-1β through its SyU domain, while PGC-1β's binding domain maps to amino acids 195-367 .

For functional ubiquitination detection:

• In vitro ubiquitination assay: Combine purified components including ATP, ubiquitin (tagged with HA or FLAG for detection), E1 enzyme, E2 enzyme, SYVN1, and the substrate protein of interest. Analyze ubiquitination products by western blotting .

• In vivo ubiquitination assay: Co-express tagged ubiquitin (FLAG-Ub) with the substrate protein (e.g., HA-PGC-1β) and either wild-type SYVN1 or the catalytically inactive mutant SYVN1(3S) in HEK 293T cells. After immunoprecipitation, detect ubiquitination by western blotting .

These techniques have successfully characterized SYVN1 interactions with multiple substrates including ATL1 and PGC-1β , providing a methodological framework for identifying new SYVN1 targets.

How can researchers effectively modulate SYVN1 expression and activity in experimental systems?

Researchers have employed multiple strategies to modulate SYVN1 expression and activity in experimental systems, each with specific advantages for different research questions:

For SYVN1 knockdown:

• RNA interference: siRNAs targeting human SYVN1 have been effectively used in cell culture models . For mouse studies, validated siRNAs for mouse Syvn1 are commercially available from providers like Ambion . Transfection is typically performed using Lipofectamine 2000 for optimal delivery.

• Viral vector-mediated shRNA delivery:

  • Lentiviral vectors (Lenti-SYVN1) for in vitro studies, showing approximately 60% knockdown efficiency in primary neurons

  • AAV vectors (AAV-SYVN1) for in vivo studies, achieving approximately 40% knockdown in striatal tissue

For SYVN1 overexpression:

• Plasmid transfection: Expression vectors containing wild-type SYVN1 or mutant variants. The C329S mutation in the RING domain creates a catalytically inactive variant useful for distinguishing E3 ligase-dependent functions .

• Domain-specific mutants: The R266A/R267A double mutation in the SyU domain decreases substrate binding without affecting E3 ligase activity, allowing researchers to separate binding from catalytic functions .

For pharmacological inhibition:
The selective SYVN1 inhibitor LS-102 has been shown to prevent weight gain in mice by abolishing the negative regulation of PGC-1β . This compound provides a valuable tool for acute inhibition studies without genetic manipulation.

For generating knockout models:
Conditional knockout strategies using Cre-loxP systems allow tissue-specific and temporally controlled deletion of Syvn1, as demonstrated in studies of adipose tissue function .

Each approach should be validated by measuring SYVN1 expression levels via Western blot or qPCR to confirm the effectiveness of the intervention.

What are the emerging therapeutic applications targeting SYVN1?

Recent research has identified several promising therapeutic applications targeting SYVN1, particularly in metabolic and neurological disorders. The most advanced therapeutic direction involves SYVN1 inhibition for obesity treatment. The selective SYVN1 inhibitor LS-102 has demonstrated efficacy in preventing weight gain in mouse models by abolishing the negative regulation of PGC-1β by SYVN1 . This approach leverages SYVN1's role in regulating mitochondrial biogenesis and energy expenditure in adipose tissue.

The mechanism involves blocking SYVN1-mediated ubiquitination of PGC-1β, which increases PGC-1β protein levels and activity, leading to:

• Upregulation of genes involved in mitochondrial function

• Increased mitochondrial number and respiration

• Enhanced basal energy expenditure in adipose tissue

Beyond obesity, emerging therapeutic applications include potential interventions for:

• Neurodegenerative disorders: Targeting the SYVN1-ATL1 axis could potentially normalize ER morphology and function in hereditary spastic paraplegia and related conditions

• ER stress-related pathologies: Modulating SYVN1 activity may help manage conditions characterized by chronic ER stress and UPR activation

• Inflammatory disorders: Given SYVN1's responsiveness to inflammatory cytokines like TNFα, IL-1, and IL-17, it represents a potential target for conditions with inflammatory components

The development of more selective and potent SYVN1 modulators remains an active area of research, with potential for significant therapeutic advances in the coming years.

What are the key methodological challenges in studying SYVN1 and how might they be addressed?

Studying SYVN1 presents several unique methodological challenges that researchers must address to advance our understanding of this important E3 ubiquitin ligase:

Challenge 1: Distinguishing degradative from non-degradative ubiquitination
SYVN1 has been shown to mediate both degradative ubiquitination (e.g., PGC-1β) and non-degradative ubiquitination (e.g., ATL1) . Differentiating between these outcomes requires careful experimental design.

Solution approach: Combine ubiquitination assays with protein stability measurements. For suspected non-degradative ubiquitination, researchers should perform cycloheximide chase experiments to monitor protein stability over time and use mass spectrometry to identify specific ubiquitination sites and chain types.

Solution approach: Utilize conditional knockout models with tissue-specific Cre drivers and temporal control (e.g., tamoxifen-inducible systems) as demonstrated in adipose tissue-specific studies . This allows precise analysis of SYVN1 function in specific contexts.

Challenge 3: ER membrane localization complicating biochemical analysis
As an ER-resident membrane protein, SYVN1 can be difficult to solubilize while maintaining its native interactions.

Solution approach: Optimize membrane protein extraction using specialized detergent combinations (e.g., digitonin with Brij 35) . For subcellular localization studies, combine biochemical fractionation with microscopy approaches to validate findings, as demonstrated in studies of GABA Aα1 localization .

Challenge 4: Multiple overlapping cellular roles
SYVN1's involvement in both ERAD and other regulatory pathways makes it difficult to isolate specific functions.

Solution approach: Develop domain-specific mutants that selectively disrupt certain functions while preserving others, such as the R266A/R267A binding mutant and C329S catalytic mutant . These tools allow researchers to dissect specific aspects of SYVN1 function in isolation.

Addressing these methodological challenges will be crucial for further elucidating SYVN1's complex roles in cellular physiology and pathology.